BioArctic AB (publ) (FRA:B9A)

Germany flag Germany · Delayed Price · Currency is EUR
27.56
-0.90 (-3.16%)
Last updated: Dec 1, 2025, 8:20 AM CET
62.12%
Market Cap2.36B
Revenue (ttm)173.33M
Net Income (ttm)90.42M
Shares Outn/a
EPS (ttm)1.02
PE Ratio26.09
Forward PE62.86
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume98
Open27.56
Previous Close28.46
Day's Range27.56 - 27.56
52-Week Range14.19 - 32.40
Betan/a
RSI57.89
Earnings DateFeb 18, 2026

About BioArctic AB

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company’s therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Employees 107
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol B9A
Full Company Profile

Financial Performance

Financial numbers in SEK Financial Statements

News

There is no news available yet.